[Role of allopurinol and rofecoxib in agranulocytosis and acute tubular necrosis]

Farm Hosp. 2003 Sep-Oct;27(5):317-22.
[Article in Spanish]

Abstract

Objective: To report the case of a patient who developed a life-threatening agranulocytosis and acute tubular necrosis after the administration of allopurinol and rofecoxib.

Case report: After minor surgery, a 70-year-old male underwent a routine blood test which encountered: anemia, leucopenia, neutropenia, thrombopenia, and altered creatinine levels. Both marrow and renal biopsies were performed, yielding the following results: acute tubular necrosis and agranulocytosis in the recovery stage. One month and a half before the aforementioned surgery a routine blood test had been performed, which showed normal values. The patient had then received allopurinol 100 mg/day for around 2 months, and rofecoxib 2.5 mg/day for 14 days.

Discussion: After ruling out other possible causes, a diagnosis of iatrogenically induced agranulocytosis and acute tubular necrosis was reached. We used a (modified) Karch-Lasagna algorithm with both drugs, and found the following imputability values: possible for rofecoxib and probable for allopurinol. In view of the widespread use of rofecoxib and COX-2 inhibitors, despite their recent availability, and of their potential role in the severe adverse effects discussed, healthcare professionals must be on the alert for the development of symptoms suggesting said or other adverse effects.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Agranulocytosis / chemically induced*
  • Allopurinol / adverse effects*
  • Cyclooxygenase Inhibitors / adverse effects*
  • Enzyme Inhibitors / adverse effects*
  • Humans
  • Kidney Tubular Necrosis, Acute / chemically induced*
  • Lactones / adverse effects*
  • Male
  • Sulfones

Substances

  • Cyclooxygenase Inhibitors
  • Enzyme Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib
  • Allopurinol